Australia's most trusted
source of pharma news
Posted 16 April 2024 PM
AstraZeneca CEO Pascal Soriot has again successfully defended an impending pay hike with a majority of the company's shareholders voting in favour of an updated remuneration structure that could see him earn more than AU$45 million this year.
A planned executive pay revolt led by investor advisory firms Glass Lewis and Institutional Shareholder Services (ISS) was easily defeated in the same way a similar campaign to stem a proposed salary increase for Soriot fell over in 2021.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.